Plain-English translation of NCT05531565 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a medication called can help people with cutaneous lupus — a form of lupus that primarily affects the skin — when standard treatments haven't worked or haven't been tolerated well. is a type of biologic drug that works by targeting immune cells involved in the disease. The study will compare this new medication to placebo (a dummy injection) to see if it can reduce skin rashes, sores, and other skin-related symptoms of lupus.
Many people with cutaneous lupus don't respond adequately to the standard antimalarial medications, or they experience side effects that prevent them from using these drugs. This trial is exploring whether this new treatment could offer a better option for patients who are stuck without good alternatives.
Participants will receive injections under the skin (subcutaneous injections) every 4 weeks, plus one additional injection at week 2. The trial is divided into two parts: an initial phase where half the participants receive the medication and half receive placebo for about 5 months, followed by an extended phase where everyone receives the active medication for several more months. Throughout the study, you'll have regular clinic visits to assess how your skin symptoms are improving and to check for any side effects.
AI-generated summary from trial data · Jun 17, 2026 · Not medical advice
United States